Eisai to Present New Research on Halaven (Eribulin) at 36th Annual San Antonio Breast Cancer Symposium
April 20, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Eisai to Present New Research on Halaven (Eribulin) at 36th Annual San Antonio Breast Cancer Symposium - JCN Newswire
Share:
Eisai to Present New Research on Halaven (Eribulin) at 36th Annual San Antonio Breast Cancer Symposium

Tokyo, Dec 5, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that new clinical study results on the company's novel anticancer agent Halaven (eribulin mesylate) will be presented during the 2013 San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 10 through 14, 2013, in San Antonio, Texas in the United States.

The studies reflect Eisai's current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug's value. The studies to be presented at this year's SABCS highlight the company's current oncology product portfolio strategy and research accomplishments in this field.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research in order to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 

 


Dec 5, 2013
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Trade Show or Conference
View more news from these Sectors: Biotech, Medical, Trade Shows, Drugs & OTC


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)